Diadema Partners »

Cytokinetics shares owned by Diadema Partners

Quarter-by-quarter ownership of Cytokinetics (CYTK) shares owned by Diadema Partners from 13F filings

Historical chart of Diadema Partners investment in Cytokinetics

Tip: Access up to 7 years of quarterly data

All positions including Cytokinetics held by Diadema Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cytokinetics by Diadema Partners

Quarter filed Position value Share count Share price at filing
2026-03-31 $17M 250k 65.91

More positions owned by Diadema Partners

United Therapeutics Corporation Put Option (UTHR)
Vertex Pharmaceuticals Incorporated (VRTX)
Viking Therapeutics (VKTX)
Capricor Therapeutics Com New Call Option (CAPR)
Abivax Sa Sponsored Ads (ABVX)
Liquidia Corporation Com New Call Option (LQDA)
Revolution Medicines (RVMD)
Apogee Therapeutics Call Option (APGE)
Bridgebio Pharma Note 1.750% 3/0
Incyte Corporation Put Option (INCY)
Kodiak Sciences Put Option (KOD)
Cytokinetics Com New Call Option (CYTK)
Johnson & Johnson (JNJ)
Cogent Biosciences (COGT)
Merck & Co Put Option (MRK)

View all positions for Diadema Partners

Top funds holding Cytokinetics

T. Rowe Price Investment Management
BlackRock
Vanguard Group
FMR
Wellington Management Company
Vanguard Portfolio Management
State Street Corporation
Vanguard Capital Management
venBio Select Advisor
Geode Capital Management
Bank of America Corporation
Rtw Investments
Armistice Capital
Integral Health Asset Management
Goldman Sachs Group

View all funds holding Cytokinetics